Svasti Haricharan, Ph.D.

Svasti Haricharan profile photo

Svasti Haricharan, Ph.D.

Co-Director and Assistant Professor
Associate Director, Training and Education

Lab Website

Svasti Haricharan's Research Focus

Breast Cancer

Dr. Haricharan's lab focuses on the role of DNA damage repair in inducing resistance to endocrine therapy in breast cancer, particularly the role of HER2/4 in mismatch repair deficiency, and in identifying early driver mutations in breast cancer formation.

Svasti Haricharan's Bio

Haricharan received her B.Sc. from Stella Maris College in Chennai, India, her M.Sc. from the University of Leicester, UK , and her Ph.D. in Molecular and Cellular Biology from Baylor College of Medicine.  Haricharan completed 2 years of postdoctoral training at MD Anderson Cancer Center studying the effect of mutation load on breast cancer, before moving to Baylor College of Medicine for her second postdoctoral position focused on breast cancer genomics, where she was promoted to Research Assistant Professor. As junior mentored faculty at Baylor College of Medicine, she developed a research program studying non-canonical roles for DNA damage repair defects in cancer. In October 2018, Haricharan joined the faculty at Sanford Burnham Prebys as an Assistant Professor in the Tumor Microenvironment and Cancer Immunology Program.

Funding awards and collaborative grants

Department of Defense Breast Research Program Breakthrough Award
Susan G Komen Career Catalyst Research Award

Honors and recognition

2015-17: SU2C Laura Ziskin Postdoctoral Fellow
2013-15: NCI Cancer Prevention Research Training Fellowship

assay tray


Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.

Oropeza E, Seker S, Carrel S, Mazumder A, Lozano D, Jimenez A, VandenHeuvel SN, Noltensmeyer DA, Punturi NB, Lei JT, Lim B, Waltz SE, Raghavan SA, Bainbridge MN, Haricharan S

Sci Adv 2023 Jun 30 ;9(26):eadf2860

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer.

Lovejoy LA, Shriver CD, Haricharan S, Ellsworth RE

Int J Environ Res Public Health 2023 Feb 7 ;20(4)

Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations.

Richardson A, Darst B, Wojcik G, Wagle N, Haricharan S

Clin Cancer Res 2023 Apr 3 ;29(7):1194-1199

Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models.

VandenHeuvel SN, Farris HA, Noltensmeyer DA, Roy S, Donehoo DA, Kopetz S, Haricharan S, Walsh AJ, Raghavan S

Soft Matter 2022 Aug 10 ;18(31):5791-5806

Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome.

Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, Burglen L, Cope H, Crawford A, Derksen A, Dure L, Gantz E, Koch-Hogrebe M, Hurst ACE, Mahida S, Marshall P, Micalizzi A, Novelli A, Peng H, Rady Children's Institute for Genomic Medicine, Rodriguez D, Robbins SL, Rutledge SL, Scalise R, Schließke S, Shashi V, Srivastava S, Thiffault I, Topol S, Undiagnosed Disease Network, Qebibo L, Wieczorek D, Cravatt B, Haricharan S, Torkamani A, Friedman J

Brain 2022 Oct 21 ;145(10):3383-3390

The DNA damage repair landscape in Black women with breast cancer.

Mazumder A, Jimenez A, Ellsworth RE, Freedland SJ, George S, Bainbridge MN, Haricharan S

Ther Adv Med Oncol 2022 ;14:17588359221075458

Show All Publications